Logo image of SRT3.DE

SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis

FRA:SRT3 - Deutsche Boerse Ag - DE0007165631 - Currency: EUR

219  -12.8 (-5.52%)

Fundamental Rating

4

SRT3 gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 16 industry peers in the Life Sciences Tools & Services industry. SRT3 has only an average score on both its financial health and profitability. SRT3 is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year SRT3 was profitable.
SRT3 had a positive operating cash flow in the past year.
SRT3 had positive earnings in each of the past 5 years.
Each year in the past 5 years SRT3 had a positive operating cash flow.
SRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFSRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

1.2 Ratios

Looking at the Return On Assets, with a value of 0.85%, SRT3 is doing worse than 68.75% of the companies in the same industry.
Looking at the Return On Equity, with a value of 3.12%, SRT3 is doing worse than 62.50% of the companies in the same industry.
SRT3's Return On Invested Capital of 3.60% is on the low side compared to the rest of the industry. SRT3 is outperformed by 81.25% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SRT3 is significantly above the industry average of 7.06%.
The 3 year average ROIC (12.95%) for SRT3 is well above the current ROIC(3.60%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 0.85%
ROE 3.12%
ROIC 3.6%
ROA(3y)5.81%
ROA(5y)5.51%
ROE(3y)23.1%
ROE(5y)21.8%
ROIC(3y)12.95%
ROIC(5y)12.44%
SRT3.DE Yearly ROA, ROE, ROICSRT3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 10 20 30

1.3 Margins

SRT3 has a Profit Margin of 2.50%. This is in the lower half of the industry: SRT3 underperforms 62.50% of its industry peers.
SRT3's Profit Margin has declined in the last couple of years.
With a Operating Margin value of 12.54%, SRT3 is not doing good in the industry: 68.75% of the companies in the same industry are doing better.
SRT3's Operating Margin has declined in the last couple of years.
SRT3's Gross Margin of 43.95% is fine compared to the rest of the industry. SRT3 outperforms 68.75% of its industry peers.
SRT3's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 12.54%
PM (TTM) 2.5%
GM 43.95%
OM growth 3Y-9.92%
OM growth 5Y-3.58%
PM growth 3Y-12.42%
PM growth 5Y-7.71%
GM growth 3Y-3.68%
GM growth 5Y-2.1%
SRT3.DE Yearly Profit, Operating, Gross MarginsSRT3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 10 20 30 40 50

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), SRT3 is creating value.
The number of shares outstanding for SRT3 remains at a similar level compared to 1 year ago.
SRT3 has about the same amout of shares outstanding than it did 5 years ago.
SRT3 has a worse debt/assets ratio than last year.
SRT3.DE Yearly Shares OutstandingSRT3.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
SRT3.DE Yearly Total Debt VS Total AssetsSRT3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B 8B

2.2 Solvency

An Altman-Z score of 2.40 indicates that SRT3 is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of SRT3 (2.40) is worse than 68.75% of its industry peers.
The Debt to FCF ratio of SRT3 is 9.45, which is on the high side as it means it would take SRT3, 9.45 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of SRT3 (9.45) is worse than 75.00% of its industry peers.
A Debt/Equity ratio of 1.66 is on the high side and indicates that SRT3 has dependencies on debt financing.
With a Debt to Equity ratio value of 1.66, SRT3 is not doing good in the industry: 87.50% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.66
Debt/FCF 9.45
Altman-Z 2.4
ROIC/WACC0.55
WACC6.5%
SRT3.DE Yearly LT Debt VS Equity VS FCFSRT3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B 4B 5B

2.3 Liquidity

SRT3 has a Current Ratio of 2.02. This indicates that SRT3 is financially healthy and has no problem in meeting its short term obligations.
SRT3 has a better Current ratio (2.02) than 81.25% of its industry peers.
A Quick Ratio of 1.13 indicates that SRT3 should not have too much problems paying its short term obligations.
The Quick ratio of SRT3 (1.13) is better than 62.50% of its industry peers.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.13
SRT3.DE Yearly Current Assets VS Current LiabilitesSRT3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SRT3 have decreased strongly by -48.38% in the last year.
Measured over the past years, SRT3 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 14.05% on average per year.
SRT3 shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -18.66%.
Measured over the past years, SRT3 shows a quite strong growth in Revenue. The Revenue has been growing by 16.74% on average per year.
EPS 1Y (TTM)-48.38%
EPS 3Y4.09%
EPS 5Y14.05%
EPS Q2Q%9.47%
Revenue 1Y (TTM)-18.66%
Revenue growth 3Y13.29%
Revenue growth 5Y16.74%
Sales Q2Q%6.71%

3.2 Future

Based on estimates for the next years, SRT3 will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.54% on average per year.
SRT3 is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.95% yearly.
EPS Next Y-17.05%
EPS Next 2Y1.9%
EPS Next 3Y9.64%
EPS Next 5Y13.54%
Revenue Next Year-1.28%
Revenue Next 2Y3.1%
Revenue Next 3Y5.47%
Revenue Next 5Y6.95%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SRT3.DE Yearly Revenue VS EstimatesSRT3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
SRT3.DE Yearly EPS VS EstimatesSRT3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 44.33, the valuation of SRT3 can be described as expensive.
68.75% of the companies in the same industry are cheaper than SRT3, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 29.07, SRT3 is valued quite expensively.
The Price/Forward Earnings ratio is 42.69, which means the current valuation is very expensive for SRT3.
SRT3's Price/Forward Earnings ratio is rather expensive when compared to the industry. SRT3 is more expensive than 81.25% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of SRT3 to the average of the S&P500 Index (22.05), we can say SRT3 is valued expensively.
Industry RankSector Rank
PE 44.33
Fwd PE 42.69
SRT3.DE Price Earnings VS Forward Price EarningsSRT3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SRT3 is valued a bit more expensive than 68.75% of the companies in the same industry.
SRT3's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 34.24
EV/EBITDA 26.47
SRT3.DE Per share dataSRT3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)3.16
EPS Next 2Y1.9%
EPS Next 3Y9.64%

More info and screens

3

5. Dividend

5.1 Amount

SRT3 has a yearly dividend return of 0.39%, which is pretty low.
Compared to an average industry Dividend Yield of 0.81, SRT3 pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.39, SRT3's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.39%

5.2 History

The dividend of SRT3 is nicely growing with an annual growth rate of 23.23%!
Dividend Growth(5Y)23.23%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

SRT3 pays out 60.94% of its income as dividend. This is not a sustainable payout ratio.
SRT3's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP60.94%
EPS Next 2Y1.9%
EPS Next 3Y9.64%
SRT3.DE Yearly Income VS Free CF VS DividendSRT3.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M
SRT3.DE Dividend Payout.SRT3.DE Dividend Payout, showing the Payout Ratio.SRT3.DE Dividend Payout.PayoutRetained Earnings

More info and screens

SARTORIUS AG-VORZUG

FRA:SRT3 (3/26/2025, 5:35:30 PM)

219

-12.8 (-5.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-17 2025-02-17/bmo
Earnings (Next)04-16 2025-04-16
Inst Owners2.79%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.40B
Analysts77.14
Price Target376.37 (71.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.39%
Yearly Dividend1.44
Dividend Growth(5Y)23.23%
DP60.94%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-22.4%
Max EPS beat(2)26.82%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.7%
Min Revenue beat(2)-4.07%
Max Revenue beat(2)2.67%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.44%
PT rev (3m)4.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.27%
Valuation
Industry RankSector Rank
PE 44.33
Fwd PE 42.69
P/S 4.93
P/FCF 34.24
P/OCF 17.75
P/B 6.14
P/tB N/A
EV/EBITDA 26.47
EPS(TTM)4.94
EY2.26%
EPS(NY)5.13
Fwd EY2.34%
FCF(TTM)6.4
FCFY2.92%
OCF(TTM)12.34
OCFY5.63%
SpS44.39
BVpS35.64
TBVpS-36.89
PEG (NY)N/A
PEG (5Y)3.16
Profitability
Industry RankSector Rank
ROA 0.85%
ROE 3.12%
ROCE 4.73%
ROIC 3.6%
ROICexc 3.87%
ROICexgc 11.44%
OM 12.54%
PM (TTM) 2.5%
GM 43.95%
FCFM 14.41%
ROA(3y)5.81%
ROA(5y)5.51%
ROE(3y)23.1%
ROE(5y)21.8%
ROIC(3y)12.95%
ROIC(5y)12.44%
ROICexc(3y)13.8%
ROICexc(5y)13.16%
ROICexgc(3y)37.98%
ROICexgc(5y)34.91%
ROCE(3y)16.99%
ROCE(5y)16.32%
ROICexcg growth 3Y-20.65%
ROICexcg growth 5Y-7.88%
ROICexc growth 3Y-23.31%
ROICexc growth 5Y-14.87%
OM growth 3Y-9.92%
OM growth 5Y-3.58%
PM growth 3Y-12.42%
PM growth 5Y-7.71%
GM growth 3Y-3.68%
GM growth 5Y-2.1%
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 1.66
Debt/FCF 9.45
Debt/EBITDA 5.52
Cap/Depr 115.38%
Cap/Sales 13.39%
Interest Coverage 2.1
Cash Conversion 115.16%
Profit Quality 575.72%
Current Ratio 2.02
Quick Ratio 1.13
Altman-Z 2.4
F-Score5
WACC6.5%
ROIC/WACC0.55
Cap/Depr(3y)173.89%
Cap/Depr(5y)164.93%
Cap/Sales(3y)13.6%
Cap/Sales(5y)12.69%
Profit Quality(3y)106.12%
Profit Quality(5y)109.16%
High Growth Momentum
Growth
EPS 1Y (TTM)-48.38%
EPS 3Y4.09%
EPS 5Y14.05%
EPS Q2Q%9.47%
EPS Next Y-17.05%
EPS Next 2Y1.9%
EPS Next 3Y9.64%
EPS Next 5Y13.54%
Revenue 1Y (TTM)-18.66%
Revenue growth 3Y13.29%
Revenue growth 5Y16.74%
Sales Q2Q%6.71%
Revenue Next Year-1.28%
Revenue Next 2Y3.1%
Revenue Next 3Y5.47%
Revenue Next 5Y6.95%
EBIT growth 1Y-36.46%
EBIT growth 3Y2.04%
EBIT growth 5Y12.57%
EBIT Next Year45.5%
EBIT Next 3Y25.3%
EBIT Next 5Y19.86%
FCF growth 1Y191.92%
FCF growth 3Y2.71%
FCF growth 5Y91.74%
OCF growth 1Y35.92%
OCF growth 3Y18.61%
OCF growth 5Y28.41%